Cargando…

Current development of COVID-19 diagnostics, vaccines and therapeutics

A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Naru, Li, Chaoqun, Hu, Yue, Li, Kangchen, Liang, Jintian, Wang, Lili, Du, Lanying, Jiang, Shibo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Institut Pasteur. Published by Elsevier Masson SAS. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200352/ https://www.ncbi.nlm.nih.gov/pubmed/32387332 http://dx.doi.org/10.1016/j.micinf.2020.05.001

Ejemplares similares

Recent Advances in the Development of Virus-Like Particle-Based Flavivirus Vaccines
por: Zhang, Naru, et al.
Publicado: (2020)

Current advancements and potential strategies in the development of MERS-CoV vaccines
por: Zhang, Naru, et al.
Publicado: (2014)

Advancement in the Development of Therapeutics Against Zika Virus Infection
por: Li, Kangchen, et al.
Publicado: (2022)

Corrigendum: Advancement in the development of therapeutics against Zika virus infection
por: Li, Kangchen, et al.
Publicado: (2022)

A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines
por: Zhang, Naru, et al.
Publicado: (2022)

Current Progress in the Development of Zika Virus Vaccines
por: Zhou, Kehui, et al.
Publicado: (2021)

Development of SARS vaccines and therapeutics is still needed
por: Jiang, Shibo, et al.
Publicado: (2013)

Middle East respiratory syndrome: current status and future prospects for vaccine development
por: Du, Lanying, et al.
Publicado: (2015)

Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines
por: Jiang, Shibo, et al.
Publicado: (2010)

Learning from the past: development of safe and effective COVID-19 vaccines
por: Su, Shan, et al.
Publicado: (2020)

Receptor-binding domain-based subunit vaccines against MERS-CoV
por: Zhang, Naru, et al.
Publicado: (2015)

The spike protein of SARS-CoV — a target for vaccine and therapeutic development
por: Du, Lanying, et al.
Publicado: (2009)

Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design
por: Ma, Cuiqing, et al.
Publicado: (2014)

An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies
por: Jiang, Shibo, et al.
Publicado: (2020)

Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain
por: Zhou, Yusen, et al.
Publicado: (2019)

Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines
por: Jiang, Shibo, et al.
Publicado: (2012)

Vaccines for the prevention against the threat of MERS-CoV
por: Du, Lanying, et al.
Publicado: (2016)

Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses
por: Wang, Ning, et al.
Publicado: (2020)

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus
por: Tang, Jian, et al.
Publicado: (2015)

From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development
por: Ma, Cuiqing, et al.
Publicado: (2020)

A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2013)

Correction: A Truncated Receptor-Binding Domain of MERS-CoV Spike Protein Potently Inhibits MERS-CoV Infection and Induces Strong Neutralizing Antibody Responses: Implication for Developing Therapeutics and Vaccines
por: Du, Lanying, et al.
Publicado: (2022)

Calling for rapid development of a safe and effective MERS vaccine
por: Hotez, Peter J., et al.
Publicado: (2014)

Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks
por: Cao, Miao, et al.
Publicado: (2021)

Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
por: Zhang, Naru, et al.
Publicado: (2016)

Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2
por: Jiang, Shibo, et al.
Publicado: (2020)

Immunotherapy of SARS based on combinations of neutralizing human monoclonal antibodies
por: Du, Lanying, et al.
Publicado: (2010)

Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant
por: Zhang, Naru, et al.
Publicado: (2022)

Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: Revealing the critical antigenic determinants in inactivated SARS-CoV vaccine
por: He, Yuxian, et al.
Publicado: (2006)

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
por: Ma, Cuiqing, et al.
Publicado: (2014)

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
por: Tai, Wanbo, et al.
Publicado: (2020)

COVID-19: Diagnostics, Therapeutic Advances, and Vaccine Development
por: Majid, Sabhiya, et al.
Publicado: (2021)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355–359; 2020)
por: Jiang, Shibo, et al.
Publicado: (2020)

Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
por: Jiang, Shibo, et al.
Publicado: (2020)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Adenovirus-based vaccines against avian-origin H5N1 influenza viruses
por: He, Biao, et al.
Publicado: (2015)

Current progress in the development of prophylactic and therapeutic vaccines
por: Li, Tingting, et al.
Publicado: (2022)

Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad‐spectrum, and safe COVID‐19 vaccines and therapeutics
por: Su, Shan, et al.
Publicado: (2021)

Development of Small-Molecule MERS-CoV Inhibitors
por: Liang, Ruiying, et al.
Publicado: (2018)

Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_070r4dmj9altnbmb6sd7vpduck